医学
西妥昔单抗
贝伐单抗
肿瘤科
危险系数
结直肠癌
内科学
无进展生存期
癌症
化疗
置信区间
作者
Francesca Battaglin,Fang‐Shu Ou,Xueping Qu,Howard S. Höchster,Donna Niedzwiecki,Richard M. Goldberg,Robert J. Mayer,Karam Ashouri,Tyler Zemla,Charles D. Blanke,Alan P. Venook,Omar Kabbarah,Heinz‐Josef Lenz,Federico Innocenti
摘要
The phase III Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial found no difference in overall survival (OS) in patients with metastatic colorectal cancer receiving first-line chemotherapy in combination with either bevacizumab or cetuximab. We investigated the potential prognostic and predictive value of
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
大力的灵雁
不能玩一下午吗
宇宙无敌大火龙
zheei
Claudia
愔愔
BowieHuang
无极微光
寻道图强
tiptip
lc
qq
伯克利芙蓉王
背后夜柳
独特奇异果
SciGPT
ff
Tttttttt
271199
zzzz
皖公网安备34019202002308
